The National Cancer Institute Opens Clinical Trial Testing Safety and Dosing of NEO-201 Antibody in Patients with Advanced Cancer
01Nov
08Jan
Precision Biologics manuscript on our NEO-201 Antibody article published in Frontiers in Immunology
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas
02Apr
Precision Biologics to Highlight Preclinical Data on NEO-201, a Neoantigen Targeting Antibody in Oral Presentation at the 110th Annual Meeting of the American Association of Clinical Research
Rockville, MD, April 2, 2017 - Precision-Biologics Inc.
29Sep
Dr. Philip Arlen to Speak at Biomarkers & Precision Medicine USA Congress
Dr. Philip Arlen to Speak at Biomarkers & Precision Medicine USA Congress - 3-4 October 2016,...
29Sep
Dr. Philip Arlen to Speak at Immune Profiling World Congress
Dr. Philip Arlen to Speak at Immune Profiling World Congress – 11-12 October 2016, Fairmont...
16Jun
Read more...
18Apr
Precision Biologics to Present Combination Immunotherapy of a Novel NEO-Epitope Antibody Targeting Ovarian and Uterine Cancer at the AACR Annual Meeting 2016
New Orleans. LA– April 17, 2016 — Precision Biologics, a clinical stage biotechnology company...
18Mar
NCI Investigators Collaborate with Moonshoot 2020
https://twitter.com/nciresearchctr/status/694520668679962624
21Jan
Precision Biologics Reaches First Clinical Trial Milestone: Immunotherapy Trial Demonstrates Encouraging Survival Rates in Patients with Metastatic Colorectal Cancer Who Failed all Standard Therapy
Over 30% of patients who failed all standard chemo and antibody therapy remain alive after...
21Dec
Precision Biologics, Announces Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI)
December 21, 2015 08:00 AM Eastern Standard Time WASHINGTON--(BUSINESS WIRE)-- Today Precision Biologics Inc,...